Brought to you by 
Tobira Therapeutics reverse merges with Regado Biosciences
01 Jun 2021
Executive Summary
Regado Biosciences Inc., a public anti-thrombotics company, and private biotech Tobira Therapeutics Inc. (hepatic and infectious diseases) reverse merged; the resulting entity will carry the Tobira name, be led by Tobira's CEO Laurent Fischer, MD, and be owned 68% by Tobira's existing stockholders (with Regado holding the rest). Regado will nominate three representatives to the board.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Reverse Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Tobira Therapeutics reverse merges with Regado Biosciences
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice